Short communicationCorrelation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
Under a Creative Commons license
open access
Abbreviations
irAE
immune related adverse event
ECOG PS
European cooperative oncology group performance status
n.s.
not significant
EGFR
epidermal growth factor receptor
ALK
anaplastic lymphoma kinase
PD-L1
programmed death-ligand 1
TKI
tyrosine-kinase inhibitor
Keywords
Non-small-cell lung cancer (NSCLC)
Nivolumab
Immune-related adverse events (irAEs)
Cited by (0)
© 2017 The Author(s). Published by Elsevier Ireland Ltd.